Jpmorgan Chase & CO Opti Nose, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Opti Nose, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 7,945 shares of OPTN stock, worth $5,323. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,945

Previous 127,343 93.76%

Holding current value

$5,323

Previous $185,000 95.68%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$0.82 - $1.44 $97,906 - $171,933	-119,398 Reduced 93.76%	7,945 $8,000
Q1 2024 May 10, 2024	BUY	$1.17 - $1.94 $88,978 - $147,537	76,050 Added 148.27%	127,343 $185,000
Q4 2023 Feb 12, 2024	SELL	$1.02 - $1.47 $20,713 - $29,851	-20,307 Reduced 28.36%	51,293 $66,000
Q3 2023 Nov 14, 2023	BUY	$0.93 - $1.38 $6,175 - $9,163	6,640 Added 10.22%	71,600 $88,000
Q2 2023 Aug 11, 2023	BUY	$1.11 - $2.05 $49,499 - $91,417	44,594 Added 218.96%	64,960 $79,000
Q1 2023 May 11, 2023	BUY	$1.63 - $2.02 $7,414 - $9,188	4,549 Added 28.76%	20,366 $39,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $3.7 $16,828 - $37,062	10,017 Added 172.71%	15,817 $29,000
Q3 2022 Nov 14, 2022	BUY	$3.43 - $4.01 $7,305 - $8,541	2,130 Added 58.04%	5,800 $21,000
Q2 2022 Aug 11, 2022	SELL	$1.76 - $3.82 $10,755 - $23,344	-6,111 Reduced 62.48%	3,670 $13,000
Q1 2022 May 11, 2022	BUY	$1.77 - $2.93 $4,375 - $7,242	2,472 Added 33.82%	9,781 $24,000
Q4 2021 Feb 10, 2022	SELL	$1.55 - $3.1 $28,509 - $57,018	-18,393 Reduced 71.56%	7,309 $12,000
Q3 2021 Nov 12, 2021	BUY	$2.35 - $3.16 $60,399 - $81,218	25,702 New	25,702 $77,000

Others Institutions Holding OPTN

# of Institutions

Shares Held

85.3M

Call Options Held

Put Options Held

View Full List

About OptiNose, Inc.

Ticker OPTN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 83,277,504
Market Cap $55.8M
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...

More about OPTN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Opti Nose, Inc. Transaction History